[Comprehensive rehabilitation of immune-mediated adverse events in cancer patients receiving checkpoint inhibitor therapy].

Autor:	Mochalova AS; Group of companies MEDSI, Otradnoe, Russia., Koneva ES; Group of companies MEDSI, Otradnoe, Russia.; Sechenov First Moscow State Medical University, Moscow, Russia., Tsvetkova AV; Group of companies MEDSI, Otradnoe, Russia.; Sechenov First Moscow State Medical University, Moscow, Russia., Senchilov MO; Sechenov First Moscow State Medical University, Moscow, Russia., Bedzhanyan AL; Petrovsky National Research Centre of Surgery, Moscow, Russia., Shatveryan GA; Petrovsky National Research Centre of Surgery, Moscow, Russia., Batukhtina EV; Petrovsky National Research Centre of Surgery, Moscow, Russia.
Jazyk:	ruština
Zdroj:	Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury [Vopr Kurortol Fizioter Lech Fiz Kult] 2022; Vol. 99 (4. Vyp. 2), pp. 30-36.
DOI:	10.17116/kurort20229904230
Abstrakt:	Objective: To evaluate adverse events and clinical effectiveness of complex rehabilitation programs in patients with malignant tumors receiving checkpoint inhibitor therapy. Material and Methods: The study included 144 cancer patients who received immunotherapy for the period from 2019 to 2021. Group 1 consisted of 72 patients who received a comprehensive rehabilitation program including physical therapy, diet therapy, psychotherapy, general magnetotherapy. Patients of the second (control) group ( n =72) did not receive rehabilitation procedures. Effectiveness of treatment was evaluated according to RECIST 1.1 criteria, safety of treatment - according to CTCAE criteria (version 5.0, 2017). To assess the quality of life (QoL), the Russian version of the EORTC QLQ-C30 questionnaire was used. Results: Mean follow-up period in the first group was 4.5 months, in the control group - 5 months. Disease progression was observed in 35 (48.6%) patients of the main group and 32 (44.4%) patients of the control group. Two (2.8%) patients in the control group demonstrated complete response to therapy. Partial response was established in both groups in 13 patients (18.1%). Stabilization of disease was detected in 24 (33.3%) and 25 (34.7%) patients, respectively. Adverse events were registered in 54 (75.0%) and 60 (83.3%) patients, respectively. Adverse events grade III-IV occurred in 9.7% and 11.1% of patients, respectively. Conclusion. I: Mmunotherapy combined with comprehensive rehabilitation program confirms high effectiveness of these drugs. We observed good tolerability of rehabilitation procedures that do not deteriorate the course of the underlying disease. However, there are certain important issues, in particular influence of rehabilitation procedures on tolerability of immunotherapy in patients with cancer.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu